Dr. Hirva Mamdani is a thoracic medical oncologist who specializes in the diagnosis and treatment of patients with malignant pleural mesothelioma, esophageal cancer, lung cancer, and other thoracic malignancies. She is the head of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute in Detroit and is the Director of Lung Cancer Screening there. She is
Dr. Scott J. Swanson is an accomplished general and thoracic surgeon at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital in Boston. He is the Director of Brigham & Women’s Minimally Invasive Thoracic Surgery Program at Brigham and Women’s Hospital and serves as Chief Surgical Officer and Thoracic Oncology Disease Center Leader for the
Dr. Pasi A. Jänne is a leading researcher and clinician in medical oncology and lung cancer. He is the Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer and sees patients at the Dana-Farber Institute Lowe Center for Thoracic Oncology. Dr. Jänne was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations.
Two of America’s most highly respected mesothelioma professionals have been named to new positions at the prestigious International Mesothelioma Interest Group (iMig). Joseph Friedberg, MD, FACS, and Melissa Culligan, RN, BSN, MSc, PhD candidate will bring the expertise that they deploy at Temple Health, the Lewis Katz School of Medicine at Temple University, and Fox
Dr. Bruce E. Johnson is a world-renowned lung cancer physician-scientist. As leader of the Lung Cancer Program for the Dana-Farber/Harvard Cancer Center in Boston, he oversees research that integrates the facilities’ patient populations and science and applies what is discovered to the treatment of patients with lung cancer, malignant mesothelioma, and other thoracic malignancies. Under
Dr. Hassan A. Khalil is a thoracic surgeon at both Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He specializes in minimally invasive surgical techniques in the treatment of thoracic and foregut diseases including malignant mesothelioma and lung cancer. He is a certified robotic console surgeon in the da Vinci Xi robotic platform and is also
Dr. David M. Jackman is a thoracic oncologist who is dedicated to improving outcomes for patients diagnosed with lung cancer, malignant pleural mesothelioma, and thymic tumors at the Dana-Farber Cancer Institute. As a physician member of the Lowe Center for Thoracic Oncology, he collaborates with experts across medical disciplines to coordinate and create a plan
Dr. Petr F. Hausner is a medical oncologist at the University of Maryland Health and is a member of the Greenebaum Comprehensive Cancer Center’s Mesothelioma and Thoracic Oncology Treatment and Research Center. His clinical specialties are hematology/oncology, thoracic oncology, gastrointestinal oncology, and cutaneous oncology. Working with a multidisciplinary team of surgeons, oncologists, and others, he
Dr. Katherine A. Scilla is a medical oncologist at the University of Maryland Medical Center and part of the Greenebaum Comprehensive Cancer Center’s Mesothelioma and Thoracic Oncology Treatment and Research Center Team. She specializes in treating chest and thoracic cancers, including malignant pleural mesothelioma, lung cancer, and thymic cancers. Dr. Scilla is part of a
Mesothelioma is a particularly challenging form of cancer that has proven extremely resistant to traditional treatment protocols. Most patients are offered multimodality treatments that include chemotherapy, and that regimen can lead to a troubling side effect referred to as ‘chemobrain.’ This week researchers have published a study that suggests that it may be caused by